Aktuellt
SENASTE
DanCann Pharma is an early-stage company with the intention to establish itself on the medical cannabis market in the Nordics and Europe. The underlying market is growing but the regulatory environment is ununified. Nevertheless, analysts see a bright future. An application has been filed for the needed licenses and approvals. A positive outcome is a trigger. We calculate a motivated value per share of DKK 6.5 for the upcoming 6-12 months. Risk is high.
LÄS MER
